Movement Alert｜Guardant Health Rises 7.47% in Regular Trading, Bernstein Sees Revenue Upside From ADLT Pricing Qualification

Market Focus07-01 22:01

On July 1, Guardant Health rose 7.47% in regular trading, trading at $161.43/share, with turnover of $204 million. The rally was driven by a bullish research note from Bernstein highlighting underappreciated revenue upside.

Bernstein initiated coverage with an Outperform rating and a $175 price target, citing that G360 ADLT pricing qualification will deliver meaningful revenue upside not yet reflected in consensus estimates. The firm's earnings forecasts exceed consensus by 6.6% for fiscal year 2027 and 12.2% for 2028, with the market notably underestimating gross margin improvement potential from the NovaSeq X platform migration, expected to contribute 350 to 550 basis points of positive impact annually.

The note adds to a string of recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer, and the inclusion of the Shield blood test in American Cancer Society colorectal cancer screening guidelines. Multiple firms including RBC Capital Markets and Evercore ISI have also issued Outperform ratings with targets ranging from $160 to $185.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165344851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-01 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165344851","market":"us","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Rises 7.47% in Regular Trading, Bernstein Sees Revenue Upside From ADLT Pricing Qualification","media":"Market Focus","content":"<p><p>On July 1, Guardant Health rose 7.47% in regular trading, trading at $161.43/share, with turnover of $204 million. The rally was driven by a bullish research note from Bernstein highlighting underappreciated revenue upside.</p><p>Bernstein initiated coverage with an Outperform rating and a $175 price target, citing that G360 ADLT pricing qualification will deliver meaningful revenue upside not yet reflected in consensus estimates. The firm's earnings forecasts exceed consensus by 6.6% for fiscal year 2027 and 12.2% for 2028, with the market notably underestimating gross margin improvement potential from the NovaSeq X platform migration, expected to contribute 350 to 550 basis points of positive impact annually.</p><p>The note adds to a string of recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer, and the inclusion of the Shield blood test in American Cancer Society colorectal cancer screening guidelines. Multiple firms including RBC Capital Markets and Evercore ISI have also issued Outperform ratings with targets ranging from $160 to $185.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Rises 7.47% in Regular Trading, Bernstein Sees Revenue Upside From ADLT Pricing Qualification</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Rises 7.47% in Regular Trading, Bernstein Sees Revenue Upside From ADLT Pricing Qualification\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-01 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 1, Guardant Health rose 7.47% in regular trading, trading at $161.43/share, with turnover of $204 million. The rally was driven by a bullish research note from Bernstein highlighting underappreciated revenue upside.</p><p>Bernstein initiated coverage with an Outperform rating and a $175 price target, citing that G360 ADLT pricing qualification will deliver meaningful revenue upside not yet reflected in consensus estimates. The firm's earnings forecasts exceed consensus by 6.6% for fiscal year 2027 and 12.2% for 2028, with the market notably underestimating gross margin improvement potential from the NovaSeq X platform migration, expected to contribute 350 to 550 basis points of positive impact annually.</p><p>The note adds to a string of recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer, and the inclusion of the Shield blood test in American Cancer Society colorectal cancer screening guidelines. Multiple firms including RBC Capital Markets and Evercore ISI have also issued Outperform ratings with targets ranging from $160 to $185.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1165344851","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165344851","pubTimestamp":1782914518,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 1, Guardant Health rose 7.47% in regular trading, trading at $161.43/share, with turnover of $204 million. The rally was driven by a bullish research note from Bernstein highlighting...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"动向提示|Guardant Health常规交易上涨7.47%，Bernstein认为ADLT定价资格带来收入上行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On July 1, Guardant Health rose 7.47% in regular trading, trading at $161.43/share, with turnover of $204 million. The rally was driven by a bullish research note from Bernstein highlighting underappreciated revenue upside.Bernstein initiated coverage with an Outperform rating and a $175 price target, citing that G360 ADLT pricing qualification will deliver meaningful revenue upside not yet reflected in consensus estimates. The firm's earnings forecasts exceed consensus by 6.6% for fiscal year 2027 and 12.2% for 2028, with the market notably underestimating gross margin improvement potential from the NovaSeq X platform migration, expected to contribute 350 to 550 basis points of positive impact annually.The note adds to a string of recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer, and the inclusion of the Shield blood test in American Cancer Society colorectal cancer screening guidelines. Multiple firms including RBC Capital Markets and Evercore ISI have also issued Outperform ratings with targets ranging from $160 to $185.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165344851","isCrawlerRequest":true}